Positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system

Copenhagen, May 23, 2017 –¬†Zealand Pharma (“Zealand”) announces positive results from a Phase 2a trial following administration of the multiple-dose version of dasiglucagon in adult patients with type 1 diabetes. Dasiglucagon is a glucagon analogue fully owned by Zealand with a unique stability profile in liquid formulation and a potential first-in-class glucagon analogue suitable for pump use.